ASLAN Signs up JHL to Provide Process Development for Asthma Treatment
November 14, 2016 at 05:53 AM EST
ASLAN Pharma of Singapore engaged JHL Biotech, a Taiwan/China CMO, to provide biologic process development services and clinical trial supplies of ASLAN004. ASLAN004 is a fully human monoclonal antibody that blocks the signaling of the IL-4 and IL-13 receptors. Work will start in 2016 in JHL's GMP-certified facility in Zhubei, Taiwan. ASLAN secured worldwide rights to ASLAN004 from CSL Behring in 2014, originally for asthma, though it is also developing the molecule to treat cancer. More details.... Share this with colleagues: // //